UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 12 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the c

Read More

Business Wire Stock Sale/Buyback News

Enjoying Merger Arbitrage Limited?

Enjoying Merger Arbitrage Limited?

Sign up then! It's quick and FREE

Have time to share an article? It's very much appreciated!!

You have Successfully Subscribed!